“Cannflavin A (CFL-A), a flavonoid present in the hemp plant Cannabis sativa L. (C. sativa), has anti-inflammatory and neuroprotective capacity.

Research continues to elucidate the anti-inflammatory effects of components of C. sativa, with evidence that plant-derived cannabinoids and terpenes can mediate anti-inflammatory activity by targeting toll-like receptor (TLR) signalling, the sensors of pathogen-associated molecules.

This study set out to determine if TLR-mediated inflammatory signalling is a CFL-A target using the endotoxin lipopolysaccharide (LPS) to induce TLR4 signalling in human THP-1-derived macrophages. TLR4 activation promoted the production of the chemokine CXCL10 and cytokines IL-1β and TNFα. Treatment with CFL-A dose-dependently attenuated TLR4-induced CXCL10 and IL-1β secretion, with our findings also indicating that the inhibitory effects of CFL-A on chemokine/cytokine secretion are in line with an NF-κB inhibitor.

This study highlights TLR4 signalling as a cannflavin target in macrophages.”

https://pubmed.ncbi.nlm.nih.gov/38780010/

“This study highlights TLR4-induced inflammatory signalling as a cannflavin target. TLR4 is a key player in controlling innate immune responses to infection, and targeted TLR4 immunotherapies are under investigation for chronic inflammatory disorders. This study indicates that CFL-A warrants further study to decipher its anti-inflammatory potential in terms of regulating innate immune inflammatory signalling. Our findings also suggest that the therapeutic value of components of the hemp plant C. sativa should be broadened to include cannflavins.”

https://www.tandfonline.com/doi/full/10.1080/14786419.2024.2358382